Am. J. Respir. Crit. Care Med., Volume 165, Number 4, February 2002, 449-455

Protective Effects of Cyclosporin A from Endotoxin-induced Myocardial Dysfunction and Apoptosis in Rats

HAROLD FAUVEL, PHILIPPE MARCHETTI, GUILLAUME OBERT, OLIVIER JOULAIN, CLAUDE CHOPIN, PIERRE FORMSTECHER, and RÉMI NEVIÈRE

INSERM U459, Faculté de Médecine 1, EA 2689, CHRU and Université de Lille 2, and Département de Physiologie, Faculté de Médecine Lille, Lille, France

Myocardial depression can be demonstrated following administration of endotoxin. Proposed mechanisms of endotoxin-induced myocardial dysfunction include the release of proinflammatory mediators, focal myocardial ischemia, and the presence of activated leukocytes within the myocardium. Recently, myocardial caspase activation and mitochondria-related apoptotic events (i.e., release of cytochrome c) were demonstrated in the failing septic heart. Here, we tested the hypothesis that immunosuppressors, cyclosporin A and tacrolimus (FK 506), would improve inflammation, heart nuclear apoptosis, and myocardial dysfunction in endotoxin-treated rats. Myocardial contractility was assessed using an isolated heart preparation. Heart leukocyte infiltration was assessed by measurement of heart myeloperoxidase activity. Leukocyte activation was studied using the intravital microscopy of the mesenteric venule. Apoptosis was detected as myocardial DNA fragmentation, downstream caspase activation, and mitochondrial cytochrome c release. Both cyclosporin A and FK 506 reduced heart leukocyte sequestration and venular adhesion in endotoxin-treated rats. Cyclosporin A, which blocks mitochondrial cytochrome c release, was able to reduce endotoxin-induced myocardial end-stage nuclear apoptosis and heart dysfunction, whereas tacrolimus had no such effects. These effects could be related to the unique properties of cyclosporin A to act on mitochondria.

This article has been cited by other articles:

				J. Suzuki, E. Bayna, H. L. Li, E. D. Molle, and W. Y.W. Lew Lipopolysaccharide Activates Calcineurin in Ventricular Myocytes J. Am. Coll. Cardiol., January 30, 2007; 49(4): 491 - 499. [Abstract] [Full Text] [PDF]

				J. Larche, S. Lancel, S. M. Hassoun, R. Favory, B. Decoster, P. Marchetti, C. Chopin, and R. Neviere Inhibition of Mitochondrial Permeability Transition Prevents Sepsis-Induced Myocardial Dysfunction and Mortality J. Am. Coll. Cardiol., July 18, 2006; 48(2): 377 - 385. [Abstract] [Full Text] [PDF]

				M. S. Joshi, M. W. Julian, J. E. Huff, J. A. Bauer, Y. Xia, and E. D. Crouser Calcineurin Regulates Myocardial Function during Acute Endotoxemia Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 999 - 1007. [Abstract] [Full Text] [PDF]

				S. Lancel, O. Joulin, R. Favory, J. F. Goossens, J. Kluza, C. Chopin, P. Formstecher, P. Marchetti, and R. Neviere Ventricular Myocyte Caspases Are Directly Responsible for Endotoxin-Induced Cardiac Dysfunction Circulation, May 24, 2005; 111(20): 2596 - 2604. [Abstract] [Full Text] [PDF]

				M. Nathan, I. Friehs, Y.-H. Choi, D. B. Cowan, H. Cao-Danh, F. X. McGowan, and P. J. del Nido Cyclosporin A But Not FK-506 Protects Against Dopamine-Induced Apoptosis in the Stunned Heart Ann. Thorac. Surg., May 1, 2005; 79(5): 1620 - 1626. [Abstract] [Full Text] [PDF]

				E. Y. Davani, D. R. Dorscheid, C.-H. Lee, C. van Breemen, and K. R. Walley Novel regulatory mechanism of cardiomyocyte contractility involving ICAM-1 and the cytoskeleton Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1013 - H1022. [Abstract] [Full Text] [PDF]

				M. J. Tobin Critical Care Medicine in AJRCCM 2002 Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 294 - 305. [Full Text] [PDF]